COPD drug showdown: taneasy vs fluimucil in new study

NCT ID NCT06828120

Completed Disease control Sponsor: Bun Yao Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed Phase 4 trial tested two mucus-thinning drugs, Taneasy and Fluimucil, in 45 adults with COPD. Participants took the granules twice daily for 14 days. The study measured how well the drugs helped clear mucus and improve breathing, using the COPD Assessment Test (CAT) score. The goal was to see if Taneasy works as well as Fluimucil for symptom relief.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Taneasy (acetylcysteine) granules and Fluimucil (acetylcysteine) granules
What this could lead to: If this works, it could show that Taneasy is as safe and effective as Fluimucil for helping COPD patients clear mucus and breathe easier.
What could go wrong: This is a small, completed Phase 4 trial with only 45 participants. Results may not apply to all COPD patients, and the 14-day treatment period is short.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)

Contacts and locations

Locations

Taipei Veterans General Hospital

Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.